Previous 10 | Next 10 |
Gainers: Alpha Tau Medical ( DRTS ) +42% . Precigen ( PGEN ) +20% . Amylyx Pharmaceuticals ( AMLX ) +18% . bluebird bio ( BLUE ) +13% . Talaris Therapeutics ( TALS ) +11% . Losers: Revelation Biosciences ( REVB ...
Amylyx Pharmaceuticals ( NASDAQ: AMLX ) stock rose ~8% on July 5 after the company said that a panel of the U.S. Food and Drug Administration is expected to meet in September to discuss its amyotrophic lateral sclerosis (ALS) medicine AMX0035. In June, the FDA exte...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA” or the “Agency”) has informed the Company that the Agency is planning to reconvene the Periph...
The Canadian approval has significantly increased the probability of a positive PDUFA despite negative AdCom. Phase 2 CENTAUR trial showed a slowing of functional decline and improved survival in ALS, a debilitating neurological disease. There could be another 40-50% upside till P...
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...
We conclude our roundtable series with Biotech and Healthcare coverage. Seven of our Marketplace contributors give their analysis and share one top idea. Look for more roundtables and analysis this summer from our community of 180+ Marketpalce services. ~ By Tim Murphy, Ma...
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It includes many rare neurological disease disorders like Alzheimer...
Do You Have These 4 Biotech Stocks on Your Watchlist? Biotech stocks have been one of the focal points of the stock market over the past two years. For obvious reasons, people and investors alike are always on the lookout for new developments against the coronavirus. But even wi...
Amylyx - founded by two Brown University students in 2013 - has developed a therapy for Amyotrophic Lateral Sclerosis, AMX-0035. Its Phase 2 CENTAUR trial data suggested the drug showed benefit on both function and survival - the first ALS drug to do so. ALS is an area of high unm...
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals Inc. Website:
- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Am...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx’ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...